For a patient diagnosed with polymyositis, the recommended first-line treatment typically involves corticosteroids Sasaki & Kohsaka 2018. These are often initiated at high doses to control inflammation and muscle weakness Sasaki & Kohsaka 2018. In many cases, immunosuppressive agents are used in conjunction with corticosteroids, or as steroid-sparing therapies, to manage the condition effectively Sasaki & Kohsaka 2018. For instance, prednisolone, a corticosteroid, has been studied in combination with immunosuppressants such as tacrolimus or cyclosporin A for the treatment of polymyositis, particularly when associated with interstitial lung disease Fujisawa et al. 2021. While specific UK guidelines for first-line polymyositis treatment were not provided in the context, the general approach in current literature emphasizes corticosteroids as foundational therapy, often combined with other immunosuppressants Sasaki & Kohsaka 2018Fujisawa et al. 2021.
Key References
- CKS - Polymyalgia rheumatica
- CKS - Ulcerative colitis
- NG35 - Myeloma: diagnosis and management
- NG129 - Crohn's disease: management
- CG163 - Idiopathic pulmonary fibrosis in adults: diagnosis and management
- (Sasaki and Kohsaka, 2018): Current diagnosis and treatment of polymyositis and dermatomyositis.
- (Fujisawa et al., 2021): Prednisolone and tacrolimus versus prednisolone and cyclosporin A to treat polymyositis/dermatomyositis-associated ILD: A randomized, open-label trial.
- (Guo et al., 2024): Pharmacological Strategies in Dermatomyositis: Current Treatments and Future Directions.